These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 3133621

  • 1. Ovarian cancer and tumor markers: sialic acid, galactosyltransferase and CA-125.
    Goldhirsch A, Berger E, Müller O, Maibach R, Misteli S, Buser K, Roesler H, Brunner K.
    Oncology; 1988; 45(4):281-6. PubMed ID: 3133621
    [Abstract] [Full Text] [Related]

  • 2. Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer.
    Petru E, Sevin BU, Averette HE, Koechli OR, Perras JP, Hilsenbeck S.
    Gynecol Oncol; 1990 Aug; 38(2):181-6. PubMed ID: 2387533
    [Abstract] [Full Text] [Related]

  • 3. Comparison of serum CA-125 and lipid-associated sialic acid (LASA-P) in monitoring patients with invasive ovarian adenocarcinoma.
    Patsner B, Mann WJ, Vissicchio M, Loesch M.
    Gynecol Oncol; 1988 May; 30(1):98-103. PubMed ID: 2452774
    [Abstract] [Full Text] [Related]

  • 4. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
    Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE.
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
    [Abstract] [Full Text] [Related]

  • 5. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
    Vardi JR, Tadros GH, Foemmel R, Shebes M.
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
    [Abstract] [Full Text] [Related]

  • 6. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K, Bian M, Zhu D, Liu W, Siu S.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
    Odunsi K, Ghamande S, Chandrasekaran EV, Ta A, Moysich KB, Driscoll D, Matta K, Lele S.
    Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
    [Abstract] [Full Text] [Related]

  • 10. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
    Patsner B, Orr JW, Mann WJ, Taylor PT, Partridge E, Allmen T.
    Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
    [Abstract] [Full Text] [Related]

  • 11. The importance of polyamine determination in monitoring malignant gynaecological tumours.
    Szarka G, Pulay T, Csömör S, Tran-Phuong-Mai, Schumann B.
    Acta Chir Hung; 1988 Sep; 29(4):365-72. PubMed ID: 3239336
    [Abstract] [Full Text] [Related]

  • 12. [Ovarian cancer--a comparison between CT diagnosis and serum tumor markers].
    Wakabayashi Y, Yachida M, Akata S, Kawana K, Kotake F, Kakizaki D, Abe K, Negishi N, Akiya K.
    Gan No Rinsho; 1988 Jan; 34(1):52-6. PubMed ID: 3422324
    [Abstract] [Full Text] [Related]

  • 13. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
    Nozawa S, Udagawa Y, Ito K, Nishimura H, Yakushiji M, Shiota M, Noda K, Yajima M, Ohkura H, Murae M.
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
    [Abstract] [Full Text] [Related]

  • 14. Clinical value of serum glycoprotein galactosyltransferase levels in different histological types of ovarian carcinoma.
    Gauduchon P, Tillier C, Guyonnet C, Heron JF, Bar-Guilloux E, Le Talaer JY.
    Cancer Res; 1983 Sep; 43(9):4491-6. PubMed ID: 6409405
    [Abstract] [Full Text] [Related]

  • 15. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P, Azen C, Lopez E, Platt LD, Karlan BY.
    Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
    [Abstract] [Full Text] [Related]

  • 16. [Tumor markers in the monitoring of ovarian cancer].
    Xu SX.
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
    [Abstract] [Full Text] [Related]

  • 17. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
    Vardi JR, Tadros GH, Malhotra C, Charney T, Shebes M, Foemmel R.
    Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
    [Abstract] [Full Text] [Related]

  • 18. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
    Jäger W, Adam R, Wildt L, Lang N.
    Arch Gynecol Obstet; 1988 Apr; 243(2):91-9. PubMed ID: 2456743
    [Abstract] [Full Text] [Related]

  • 19. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
    Nozawa S, Udagawa Y, Ito K, Susumu N, Sasaki H, Aoki D.
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
    [Abstract] [Full Text] [Related]

  • 20. [Serum level of the tumor marker CA 125 in ovarian pathology].
    Bagni B, Pansini FS, Feggi LM, Prandini N, Mollica G.
    Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.